CoChat

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

Open access
Hopewell, Jemma C., Parish, Sarah, Offer, Alison, Link, Emma, Clarke, Robert, Lathrop, Mark, Armitage, Jane, Collins, Rory, on behalf of the MRC/BHF Heart Protection Study Collaborative Group · 2013 · European Heart Journal
Cited by 106

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

AIMS: Statins reduce LDL cholesterol (LDL-C) and the risk of vascular events, but it remains uncertain whether there is clinically relevant genetic variation in their efficacy. This study of 18 705 individuals aims to identify genetic variants related to the lipid response to simvastatin and assess their impact on vascular risk response. METHODS AND RESULTS: A genome-wide study of the LDL-C and apolipoprotein B (ApoB) response to 40 mg simvastatin daily was performed in 3895 participants in the Heart Protection Study, and the nine strongest associations were tested in 14 810 additional participants. Selected candidate genes were also tested in up to 18 705 individuals. There was 90% power to detect differences of 2.5% in LDL-C response (e.g. 42.5 vs. 40% reduction) in the genome-wide study and of 1% in the candidate gene study. None of the associations from the genome-wide study was replicated, and nor were significant associations found for 26 of 36 candidates tested. Novel lipid response associations with variants in LPA, CELSR2/PSRC1/SORT1, and ABCC2 were found, as well as confirmatory evidence for published associations in LPA, APOE, and SLCO1B1. The largest and most significant effects were with LPA and APOE, but were only 2-3% per allele. Reductions in the risk of major vascular events during 5 years of statin therapy among 18 705 high-risk patients did not differ significantly across genotypes associated with the lipid response. CONCLUSIONS: Common genetic variants do not appear to alter the lipid response to statin therapy by more than a few per cent, and there were similar large reductions in vascular risk with simvastatin irrespective of genotypes associated with the lipid response to simvastatin. Consequently, their value for informing clinical decisions related to maximizing statin efficacy appears to be limited.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehs344

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 106

Metadata

Authors
Hopewell, J. C., Parish, S., Offer, A., Link, E., Clarke, R., Lathrop, M., Armitage, J., Collins, R., & on behalf of the MRC/BHF Heart Protection Study Collaborative Group
Venue
European Heart Journal
Published
2012-10-24
Volume
34
Issue
13
Pages
982-992
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2114951165
Cited by
106
References
7
FWCI
11.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. https://app.cochat.ai/papers/10.1093/eurheartj/ehs344
The paper
Hopewell, J. C., Parish, S., Offer, A., Link, E., Clarke, R., Lathrop, M., Armitage, J., Collins, R., & on behalf of the MRC/BHF Heart Protection Study Collaborative Group. (2013). Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehs344

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.